Project Grant K08NS144524
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $220K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
- The National Cancer Institute awarded Mayo Clinic a cooperative agreement totaling $688,661 on June 9, 2026, to develop and validate cell-free DNA approaches for prospective detection and monitoring of malignant peripheral nerve sheath tumors (MPNST) and their precursor lesions in neurofibromatosis type 1 (NF1) patients under the Cancer Detection and Diagnosis Research program (CFDA 93.394). Mayo Clinic will conduct three integrated research objectives: determining whether integrative...
- The National Institute of Neurological Disorders and Stroke, a division of the Department of Health and Human Services National Institutes of Health, awarded Mayo Clinic Jacksonville $242,580 on August 24, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds research to decode and target the molecular mechanisms of TRAF7/KLF4 driver mutations in meningioma. The project uses CRISPR-CAS9 gene editing to introduce...
- The National Institute of Neurological Disorders and Stroke awarded Cincinnati Children's Hospital Medical Center $445,500 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to conduct genetic dissection of the rasopathy gene NF1 and MAPK pathway activation in cortical cell fate. The research investigates mechanisms regulating early stages of gliogenesis from cortical progenitors using mouse models. Three specific...
- The National Cancer Institute awarded Mayo Clinic $565,423 on August 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate individualized DNA junction-based liquid biopsies for monitoring glioblastoma and high-grade gliomas during and after treatment. The research addresses a clinical gap in glioma surveillance. Current magnetic resonance imaging monitoring using RANO 2.0 criteria lacks sensitivity and specificity for detecting early disease...
- The National Institute of Neurological Disorders and Stroke awarded Mayo Clinic $622,784 on July 21, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate acute and chronic repercussions of spinal cord stimulation following spinal cord injury. The research quantifies blood pressure instability after spinal cord injury, which interrupts descending autonomic regulatory signals and causes loss of consciousness, stroke,...
- The National Institute of Neurological Disorders and Stroke awarded Emory University $195,625 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to develop a human schwannoma-on-chip platform for real-time monitoring of tumor-nerve interactions. Schwannomatosis is a rare neurological disease characterized by peripheral nerve tumors that cause debilitating pain and progressive neurological deficits, with current...
- The National Institute of Neurological Disorders and Stroke awarded the Sloan-Kettering Institute for Cancer Research $484,000 on May 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds research characterizing and inhibiting interactions of the alpha-secretase ADAM17 with the neuronal-myelin signaling complex upon spinal cord injury. The study investigates how myelin-associated inhibitors—including...
- The National Cancer Institute awarded the Trustees of Indiana University $137,576 on January 21, 2026, under the Cancer Research Manpower program (CFDA 93.398) to fund research evaluating the role of T cells in neurofibromatosis type 1 (NF1)–associated peripheral nerve sheath tumor progression. The research examines molecular and cellular interactions governing progression along the peripheral nerve sheath tumor continuum, specifically investigating how alterations in immune surveillance...
- The National Cancer Institute awarded the Trustees of Indiana University $113,244 on December 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to conduct research on regulators of differentiation failure in NF2-mutant neural progenitors as a mechanism underlying spinal ependymoma formation. The recipient will perform a CRISPR kinase and transcription factor knockout screen in a neuroepithelial stem cell model with induced NF2 mutations to identify regulatory components...
- The National Institute of Neurological Disorders and Stroke, a component of the National Institutes of Health, awarded $613,912 to the Trustees of Indiana University on April 8, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds research to identify DLK1 as a biomarker for malignant peripheral nerve sheath tumor (MPNST) risk stratification in neurofibromatosis type 1 patients. The research addresses the clinical...